Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)

被引:245
作者
Albers, John J. [1 ]
Slee, April [2 ]
O'Brien, Kevin D. [3 ]
Robinson, Jennifer G. [4 ]
Kashyap, Moti L. [5 ,6 ]
Kwiterovich, Peter O., Jr. [7 ,8 ]
Xu, Ping [2 ]
Marcovina, Santica M. [1 ]
机构
[1] Univ Washington, Dept Med, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA 98109 USA
[2] Axio Res, Seattle, WA USA
[3] Univ Washington, Dept Med, Seattle, WA 98109 USA
[4] Univ Iowa, Lipid Res Clin, Iowa City, IA USA
[5] Vet Affairs Med Ctr, Long Beach, CA USA
[6] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
[7] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA
[8] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
关键词
apolipoproteins; cardiovascular risk; lipoprotein(a); niacin; simvastatin; RISK; CHOLESTEROL;
D O I
10.1016/j.jacc.2013.06.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to examine the relationship between baseline and on-study apolipoproteins (apo) A-1 and B and lipoprotein(a) [Lp(a)] levels and the development of subsequent cardiovascular (CV) events in the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) trial. Background Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1. Methods Individuals with CV disease and low baseline levels of high-density lipoprotein cholesterol were randomized to simvastatin plus placebo or simvastatin, plus extended-release niacin ([ERN], 1,500 to 2,000 mg/day), with ezetimibe added as needed, in both groups, to maintain an on-treatment low-density lipoprotein cholesterol in the range of 40 to 80 mg/dl. Hazard ratios (HRs) were used to evaluate the relationship between levels of apoA-1, apoB, and Lp(a), and CV events in each treatment group. Results Baseline apoB and the apoB/apoA-I ratio were significantly predictive of CV events only for the placebo group (HR: 1.17 [p = 0.018] and HR: 1.19 [p = 0.016]). Baseline and on-study Lp(a) were predictive of CV events in both simvastatin plus placebo (baseline HR: 1.24 [p = 0.002] and on-study HR: 1.21 [p = 0.017]) and the simvastatin plus ERN group (baseline HR: 1.25 [p = 0.001] and on-study HR: 1.18 [p = 0.028]). The ERN modestly increased 1-year apoA-1 (7%), decreased apoB (13%), decreased the ApoB/ApoA-1 ratio (19%), and decreased Lp(a) 21%, but did not reduce CV events. Conclusions Lp(a) was associated with increased CV risk in both treatment groups indicating that it contributes to residual CV risk. However, there was no evidence that ERN reduced CV risk, despite favorable lipoprotein changes. (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:1575 / 1579
页数:5
相关论文
共 10 条
[1]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[2]  
Erqou S, 2009, JAMA-J AM MED ASSOC, V302, P412, DOI 10.1001/jama.2009.1063
[3]   HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment [J].
Haynes, Richard ;
Jiang, Lixin ;
Hopewell, Jemma C. ;
Li, Jing ;
Chen, Fang ;
Parish, Sarah ;
Landray, Martin J. ;
Collins, Rory ;
Armitage, Jane .
EUROPEAN HEART JOURNAL, 2013, 34 (17) :1279-1291
[4]   Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events [J].
Jaeger, Beate R. ;
Richter, Yvonne ;
Nagel, Dorothea ;
Heigl, Franz ;
Vogt, Anja ;
Roeseler, Eberhard ;
Parhofer, Klaus ;
Ramlow, Wolfgang ;
Koch, Michael ;
Utermann, Gerd ;
Labarrere, Carlos A. ;
Seidel, Dietrich .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2009, 6 (03) :229-239
[5]   Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction [J].
Kamstrup, Pia R. ;
Tybjaerg-Hansen, Anne ;
Steffensen, Rolf ;
Nordestgaard, Borge G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (22) :2331-2339
[6]   Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study [J].
Lamon-Fava, Stefania ;
Marcovina, Santica M. ;
Albers, John J. ;
Kennedy, Hal ;
DeLuca, Carl ;
White, Charles C. ;
Cupples, L. Adrienne ;
McNamara, Judith R. ;
Seman, Leo J. ;
Bongard, Vanina ;
Schaefer, Ernst J. .
JOURNAL OF LIPID RESEARCH, 2011, 52 (06) :1181-1187
[7]   EFFECTS OF LOWERING ELEVATED LDL CHOLESTEROL ON THE CARDIOVASCULAR RISK OF LIPOPROTEIN(A) [J].
MAHER, VMG ;
BROWN, BG ;
MARCOVINA, SM ;
HILLGER, LA ;
ZHAO, XQ ;
ALBERS, JJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (22) :1771-1774
[8]  
MARCOVINA SM, 1995, CLIN CHEM, V41, P246
[9]   Lipoprotein(a) as a cardiovascular risk factor: current status [J].
Nordestgaard, Borge G. ;
Chapman, M. John ;
Ray, Kausik ;
Boren, Jan ;
Andreotti, Felicita ;
Watts, Gerald F. ;
Ginsberg, Henry ;
Amarenco, Pierre ;
Catapano, Alberico ;
Descamps, Olivier S. ;
Fisher, Edward ;
Kovanen, Petri T. ;
Kuivenhoven, Jan Albert ;
Lesnik, Philippe ;
Masana, Luis ;
Reiner, Zeljko ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Tybjaerg-Hansen, Anne .
EUROPEAN HEART JOURNAL, 2010, 31 (23) :2844-U14
[10]   Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease [J].
Tregouet, David-Alexandre ;
Koenig, Inke R. ;
Erdmann, Jeanette ;
Munteanu, Alexandru ;
Braund, Peter S. ;
Hall, Alistair S. ;
Grosshennig, Anika ;
Linsel-Nitschke, Patrick ;
Perret, Claire ;
DeSuremain, Maylis ;
Meitinger, Thomas ;
Wright, Ben J. ;
Preuss, Michael ;
Balmforth, Anthony J. ;
Ball, Stephen G. ;
Meisinger, Christa ;
Germain, Cecile ;
Evans, Alun ;
Arveiler, Dominique ;
Luc, Gerald ;
Ruidavets, Jean-Bernard ;
Morrison, Caroline ;
van der Harst, Pim ;
Schreiber, Stefan ;
Neureuther, Katharina ;
Schaefer, Arne ;
Bugert, Peter ;
El Mokhtari, Nour E. ;
Schrezenmeir, Juergen ;
Stark, Klaus ;
Rubin, Diana ;
Wichmann, H-Erich ;
Hengstenberg, Christian ;
Ouwehand, Willem ;
Ziegler, Andreas ;
Tiret, Laurence ;
Thompson, John R. ;
Cambien, Francois ;
Schunkert, Heribert ;
Samani, Nilesh J. .
NATURE GENETICS, 2009, 41 (03) :283-285